Schwarzbach V, Lenk K, Laufs U (2020) Methamphetamine-related cardiovascular diseases. ESC Heart Fail 7(2):407–414
Ben-Yehuda O, Siecke N (2018) Crystal methamphetamine: a drug and cardiovascular epidemic. JACC Heart Fail 6(3):219–221
Kevil CG et al (2019) Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol 39(9):1739–1746
Zhao SX et al (2018) Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy. JACC Heart Fail 6(3):209–218
Freeling JL, McFadden LM (2020) The emergence of cardiac changes following the self-administration of methamphetamine. Drug Alcohol Depend 212:108029
Paratz ED et al (2017) Is an abnormal ECG just the tip of the ice-berg? examining the utility of electrocardiography in detecting methamphetamine-induced cardiac pathology. Heart Lung Circ 26(7):684–689
JafariGiv M (2017) Exposure to amphetamines leads to development of amphetamine type stimulants associated cardiomyopathy (ATSAC). Cardiovasc Toxicol 17(1):13–24
Jones CM, Compton WM, Mustaquim D (2020) Patterns and characteristics of methamphetamine use among adults - United States, 2015–2018. MMWR Morb Mortal Wkly Rep 69(12):317–323
Zhao SX et al (2021) Socioeconomic burden of rising methamphetamine-associated heart failure hospitalizations in California from 2008 to 2018. Circ Cardiovasc Qual Outcomes 14(7):e007638
Nishimura M et al (2019) Characteristics and outcomes of methamphetamine abuse among veterans with heart failure. Am J Cardiol 124(6):907–911
Paulus MP, Stewart JL (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiat 77(9):959–966
Wijetunga M et al (2003) Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol 41(7):981–986
Hong R, Matsuyama E, Nur K (1991) Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 265(9):1152–1154
Srikanth S, Barua R, Ambrose J (2008) Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology 109(3):188–192
Chen JP (2007) Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol 19(4):E89-92
Haning W, Goebert D (2007) Electrocardiographic abnormalities in methamphetamine abusers. Addiction 102(Suppl 1):70–75
Panenka WJ et al (2013) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129(3):167–179
Shaerzadeh F et al (2018) Methamphetamine neurotoxicity, microglia, and neuroinflammation. J Neuroinflammation 15(1):341
Sambo DO et al (2017) The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission. Nat Commun 8(1):2228
Reddy PKV et al (2020) Clinical characteristics and management of methamphetamine-associated cardiomyopathy: state-of-the-art review. J Am Heart Assoc 9(11):e016704
Jiang JP, Downing SE (1990) Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms. Yale J Biol Med 63(6):581–591
CAS PubMed PubMed Central Google Scholar
Brown JM, Yamamoto BK (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99(1):45–53
Won S et al (2013) Methamphetamine-associated cardiomyopathy. Clin Cardiol 36(12):737–742
Kaye S et al (2008) Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 103(8):1353–1360
Darke S, Duflou J, Kaye S (2017) Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alcohol Depend 179:174–179
Potula R et al (2010) Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol 185(5):2867–2876
Phillips TJ et al (2021) Confirmation of a causal Taar1 allelic variant in addiction-relevant methamphetamine behaviors. Front Psychiatry 12:725839
Seo JW et al (2016) Methamphetamine induces the release of endothelin. J Neurosci Res 94(2):170–178
Fehler M et al (2010) Identification of trace-amine-associated receptors (TAAR) in the rat aorta and their role in vasoconstriction by beta-phenylethylamine. Naunyn Schmiedebergs Arch Pharmacol 382(4):385–398
Herbert AA, Kidd EJ, Broadley KJ (2008) Dietary trace amine-dependent vasoconstriction in porcine coronary artery. Br J Pharmacol 155(4):525–534
Nguyen EC et al (2005) Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 49(5):638–645
Abdullah CS et al (2020) Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function. Commun Biol 3(1):682
Pontisso I, Combettes L (2021) Role of Sigma-1 receptor in calcium modulation: possible involvement in cancer. Genes 12(2):139
Hong WC et al (2017) The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem 292(27):11250–11261
Abdullah CS et al (2018) Cardiac dysfunction in the Sigma 1 receptor knockout mouse associated with impaired mitochondrial dynamics and bioenergetics. J Am Heart Assoc 7(20):e009775
Bhuiyan MS, Tagashira H, Fukunaga K (2013) Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure. J Pharmacol Sci 121(3):177–184
Hart CL et al (2008) Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33(8):1847–1855
Osekowski M et al (2022) A comprehensive approach to managing methamphetamine-associated cardiomyopathy. Am J Cardiovasc Drugs
Heidenreich Paul A et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 79(17):e263–e421
Gentry WB et al (2006) Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 6(6):968–977
Sevak RJ et al (2011) Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole. J Clin Psychopharmacol 31(4):470–480
留言 (0)